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Background: Plasmodium vivax has traditionally been considered virtually absent from Western and Central Africa,
due to the absence of the Duffy blood group in most of the population living in these areas. Recent reports,
however, suggest the circulation of P. vivax in sub-Saharan Africa.
Methods: Giemsa/Field-stained smears from febrile patients recruited in five different cities (Goundam,
Tombouctou, Gao, Bourem and Kidal) pertaining to three regions from Northern Mali were examined. Nested-PCR
and DNA sequence analyses of selected samples were performed to fully confirm the presence of P. vivax
infections.
Results: Results demonstrated the presence of P. vivax infections in close to 30% of the cases as detected by
Giemsa/Field-stained smears and nested-PCR and DNA-sequence analyses of selected samples unequivocally
confirmed the presence of P. vivax.
Conclusions: The diagnostics of this human malaria parasite should be taken into account in the context of malaria
control and elimination efforts, not only in Mali, but also in sub-Saharan Africa.
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Plasmodium vivax is the most widely distributed human
malaria parasite and responsible for 100–300 million
clinical cases yearly, including severe disease and death.
It has been estimated that 2.85 billion people are
exposed to some risk of P. vivax transmission worldwide
and of those circa 0.10 billion (3.5%) are in the African
region where transmission is considered stable (≥0.1 case
per 1,000 people per annum) [1]. Of note, it is widely
accepted that P. vivax is largely absent in Central and
Western Africa, mostly as a result of the absence of the
Duffy blood group, a blood receptor hitherto considered* Correspondence: hernandoa.delportillo@cresib.cat; okd@icermali.org
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reproduction in any medium, provided the orindispensable for the invasiveness of P. vivax into red
blood cells, as more than 90% of the population in this
area are believed to be Duffy negative [2]. In recent
years, however, increasing evidence of the circulation of
P. vivax episodes affecting Duffy negative individuals has
appeared, including one from Africa [3-5]. Ever since,
other reports have demonstrated the presence of
P. vivax infections in sub-Saharan Africa [6-9].
Mali is a landlocked nation in West Africa divided into
eight regions and almost 15 million people with inter-
national borders with seven African countries. Of re-
levance, some reports have indicated the presence of
P. vivax infections in this country [10-12]. Here, fol-
lowing a survey in the northern population of Mali,
where local transmission of P. vivax was also suspected,
blood samples were collected from febrile patients and
stained. Giemsa/Field-stained blood smears were ana-
lysed for specific P. vivax diagnosis by microscopy.
Moreover, genomic DNA extracted from the same
smears used in microscopy was used as templates forral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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species infecting humans. Last, amplified fragments were
cloned and sequenced. Results unequivocally confirm
and extend previous observations of P. vivax in Mali.Methods
Samples collection and microscopy diagnosis
As part of routine National Malaria Control Programme
surveillance procedures, Giemsa and/or Field-stained
thick and thin blood smears from three different regions
of Mali: Tombouctou, Gao and Kidal were collected in
five health care facilities within these regions (Figure 1).
They were afterwards collected and sent to the Malaria
Research and Training Centre in Bámako to assess the
quality of microscopy diagnosis and survey the malaria
incidence. Samples belonging to 88 febrile patients
from these health care facilities were randomly chosen
and re-examined in a centralized manner at the Barce-
lona Centre for International Health Research labora-
tories (Barcelona, Spain) following the World Health
Organization’s operational manual 2011 for universalFigure 1 Vivax malaria in Mali. Geographical regions where this study w
P. vivax was also recently detected [10] is circled in blue. Adaptation from t
creativecommons.org/licenses/by-sa/3.0/de/deed.en)], via Wikimedia Commaccess to malaria diagnostic testing. The microscopic
diagnosis of these specimens performed in Mali was
not available to researchers in Barcelona with the ex-
ception of one sample. Therefore, blood smears were
studied blindly assessing the presence or absence of
parasites with morphological features of P. vivax mature
stages using a Nikon ECLIPSE 50i microscope. Pictures
were taken with a Nikon photomicrography camera
model DS-5M. Smears were reported as negative after
the examination of the specimen in approximately 200
oil immersion fields, and as positive when at least one
parasite with highly suggestive features of P. vivax ma-
ture stages was observed.Genomic extraction
Genomic DNA from 25 smears pertaining to different
patients was obtained by scrapping off half of the surface
of the smear with a scalpel and re-suspending in 100 μl
of phosphate buffered saline (PBS). Genomic DNA was
extracted using QIAamp DNA mini kit (Qiagen) accord-
ing to manufacturer’s instructions.as conducted are circled in red. Ménaka, the geographical area where
he map produced by NordNordWest [CC-BY-SA-3.0-de (http://
ons.
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Identification of the four species was performed by
nested-PCR [13]. Plasmodium vivax positive agarose
bands were extracted using QIAEX II Gel Extraction Kit
(Qiagen) and cloned using TOPO TA Cloning Kit and
pGEM-T Easy Vector Systems. Cloned plasmids were
sequenced using commercial primers FM13 and T7.
Sequence alignment and phylogenetic trees were per-
formed using Lasergene software (DNASTAR Corp.,
Madison, WI). Plasmodium spp small subunit rRNA
(SSU RNA) sequences were obtained from PlasmoDB
version 8.2 and GenBank. Plasmodium vivax: PVX_096002,
PVX_097020, PVX_088869, PVX_079693; Plasmodium
cynomolgi: FJ619084.1; Plasmodium falciparum: JQ627152.1;
Plasmodium knowlesi: FJ619098.1; Plasmodium malariae:
GU815531.1; Plasmodium ovale: JF894411.1; Plasmodium
yoelii: AF266261.1. Sequences were analysed by the parsi-
mony method using 100 heuristic random addition repli-
catives and 100 bootstrap replicates.
Results
A total of 88 Giemsa/Field-stained slides were randomly
selected from febrile malaria patients as part of routine
National Malaria Control Programme surveillance pro-
cedures in Mali. Strikingly, out of 88 samples analysed,
25 (28.4%) contained mature stages (readily detected in
less than 20 high power fields examined) suggestive
of P. vivax (Figure 2A, Additional file 1, Table 1).
As P. ovale and P. malariae infections are commonly
found in Western and Central Africa, genomic DNA
was extracted from the 25 slides for P. vivax and
nested-PCR analysis was performed using probes for
the four Plasmodium spp (Figure 2B). As a positive
control, gDNA from a P. vivax slide from Brazil was
also extracted. Fifteen samples pertaining to Goudam,
Tombouctou and Gao were PCR positive for P. vivax.
Among them, eleven contained mixed infections withFigure 2 Plasmodium vivax infections in Northern Mali. A. Giemsa-stain
from a nested-PCR assay using P. vivax-specific primers. Molecular weight in
corresponding to P. vivax (arrow) is shown to the left.P. falciparum, four were positive for P. malariae and
none for P. ovale (Table 2).
To fully confirm these results, amplified fragments
from eleven samples were cloned and sequenced. Signifi-
cantly, similarity analysis with available P. vivax SSU
RNA gene sequences from the SalI strain (PVX_088869,
PVX_096002, PVX_097020, PVX_079693) demonstrated
that sequences from Mali corresponded to P. vivax and
that there were several polymorphisms (Additional file
2). Consistent with the existence of different SSU RNA
genes in P. vivax [14], phylogenetic analysis tested by
bootstrap showed that sequences fell into major genetic
clusters of SSU RNA P. vivax genes branching-out
from SSU RNA sequences of other Plasmodium spe-
cies (Figure 3). Together, these results unequivocally
confirmed the presence of P. vivax infections in Mali.
Discussion
The presence of P. vivax malaria in sub-Saharan Africa
has been largely neglected since it was demonstrated
that lack of expression of the Duffy blood-group corre-
lated with the absence of P. vivax infections [2]. More-
over, it has been suggested that P. vivax is of African
origin thus driving fixation of the Duffy negative pheno-
type [15]. Recent evidence, however, has called upon to
revise this suggestion as it strongly indicates that P.
vivax may instead be of Asian origin [16,17]. Its increas-
ingly recognized presence in Africa may, therefore, be
related to its newly acknowledged capacity of exploiting
new alternative invasion pathways among populations in
this continent. Regardless of the geographical origin of
P. vivax and the pathway for entrance into reticulocytes,
it is clear that the presence of P. vivax in Africa is prob-
ably underestimated.
A few reports, of variable quality, have described infec-
tions by P. vivax in Mali [10-12]. An early indication
of its presence came from the description of Russian
doctors in the region of Gao in the 1950s (OD,ed images of samples from different regions. B. Amplified fragments
base pairs (bp) of predicted amplified size fragments (117 bp)
Table 1 Total numbers and analyses of samples obtained




Bourem 20 1/20 0/1 ND
Gao 46 7/12 5/7 5/15
Goundam 22 3/8 3/3 3/15
Kidal 34 5/30 0/5 ND
Tombouctou 58 9/18 7/9 3/15
Total 180 25/88 15/25 11/15
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fection in an eight year-old girl was reported in Kidal
during a survey in 1988 in Trans-Sahara [12]. The mi-
croscopy diagnosis of this patient was confirmed in
two European reference laboratories at Marseille and
London. More recently, Koita et al. performed two
cross-sectional studies in the North-Eastern region of
Mali, reporting over 10% prevalence rates of P. vivax
infections as detected by Giemsa-stained smear [10].
However, and noteworthy, with the exception of one
single sample, exclusion of the potentially confounding
and morphologically similar P. ovale and P. malariae
species were not systematically performed using mo-
lecular techniques.
Microscopy evaluation of samples examined here simi-
larly suggested the presence of parasite blood stages re-
sembling P. vivax. However, and as an important
limitation of only using such diagnostic techniques, it
seems difficult to exclude that these stages may not cor-
respond to P. ovale species. P. ovale has been frequently
reported in this particular region of Africa and even
though distinct ameboid trophozoites and number of
nuclei per single schizont can be used as criteria for
species-specific diagnostics, this remains very challen-
ging in most thick-blood smears. Thus, nested-PCR and
DNA sequence analyses were performed to unambigu-
ously demonstrate P. vivax infections in Mali. Amplified
fragments of sizes corresponding to the SSU RNA gene
of P. vivax were observed in close to 28% of infections.
Moreover, sequence similarity and phylogenetic analysesTable 2 Nested-PCR identification of Plasmodium spp. in 25 sa
regions in Northern Mali
Cities P. falciparum P. vivax Mixed P. falcip
P. vivax
Bourem 1/1 0/1 0/1
Goundam 0/3 0/3 3/3
Tomboctou 0/9 4/9 1/9
Kidal 4/5 0/5 0/5
Gao 1/7 0/7 5/7
Total 6/25 4/25 9/25unequivocally confirmed that these fragments corre-
sponded to P. vivax sequences.
These findings are of important public health rele-
vance. In recent years, the scientific attention of the mal-
aria community has shifted from a focus on malaria
control to specific efforts aiming at global malaria eradi-
cation [18]. However, it is important to consider that
efforts needed to control P. vivax will surely exceed
those necessary to control P. falciparum as transmission
of this species is possible even before the appearance of
clinical symptoms, and can also occur irrespective of
adequate asexual parasite clearance as a result of
hypnozoite-derived relapses. Indeed, the adequate treat-
ment of P. vivax infections includes the addition of a
full 14-day long course of primaquine (PQ), the only
to date registered drug that can achieve the radical
cure of the hepatic hypnozoites, responsible for unpre-
dictable relapses and subsequent morbidity, and a drug
that has potent gametocytocidal activity. Without the
radical cure, hepatic hypnozoites will maintain those
infected individuals as infectious, and thus prone to
maintain transmission and develop new disease epi-
sodes. PQ is unfortunately an unsafe drug, and can
lead to severe haemolysis when administered blindly to
glucose-6-phosphate dehydrogenase (G6PD) deficient
patients, a genetic deficiency particularly frequent in
sub-Saharan Africa, limiting therefore its widespread
use unless guaranteeing prior screening of this defi-
ciency. As no rapid G6PD deficiency diagnostic tests
exist to date, dismissing its risks prior to PQ adminis-
tration appears unfeasible, and adequate treatment of
P. vivax episodes unguaranteed, adding further com-
plexity to the control programmes in place in many
African settings. In Mali, the spread of P. vivax in the
northern part of the country will complicate the possi-
bility of malaria elimination. The current malaria con-
trol programme has no reference to vivax malaria. The
findings reported here will push further to a revision
of the policy document. New tools will be needed (the
use of mass drug administration of primaquine for ex-
ample) and access to the target population is a major
public health issue. All the laboratory technicians inmples from five different cities pertaining to three
arum + Mixed P. falciparum +
P. malariae
Mixed P. falciparum +







Figure 3 Bootstrapped phylogenetic rooted tree constructed by the parsimony method for the SSUr RNA sequences of Plasmodium
vivax from Mali. Horizontal branch lengths between nodes correspond to the number of shared derived changes. Slide52-72_clone1-3 represent
the slide from Mali were we obtained the gDNA and the number of clone that was sequenced. SlideBrazil, positive P. vivax control. 18S_PVX
samples were obtained from PlasmoDB 8.2. Other Plasmodium spp. 18S sequences were obtained from GenBank. Accession Numbers for all of
them are listed in Methods.
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for microscopic diagnostic.
An important limitation of this work is the inability to
link such confirmed P. vivax infections with the Duffy
and G6PD phenotypes of the individuals affected. In-
deed, the presence of Duffy positive ethnic groups in
central and West Africa as in the case of the Moors in
Mauritania [8] or other Ethnic groups that may be
present in Mali could entirely account for P. vivax trans-
mission in the area, and would not necessarily imply that
this species has found alternative mechanisms to infect
Duffy-negative individuals. Prospective studies furtherinvestigating the Duffy and G6PD status and its relation
to species-specific malaria risk are, therefore, urgently
needed.
In Mali, P. vivax infections can no longer be consid-
ered rare or anecdotal, and their diagnosis and adequate
management need to be included as part of routine sur-
veillance activities. This should be coupled with an ad-
equate knowledge of the Duffy and G6PD status in the
population, so as to assess the risks that the introduction
of PQ treatment could entail to the population. Malaria
control efforts in the area will surely fail unless species-
specific measures are put in place.
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Additional file 1: Vivax malaria in Mali. Additional illustrative
images of Giemsa-stained smear P. vivax positive samples from
different regions.
Additional file 2: Clustal W Alignment of SSU RNA sequences from
different Plasmoidum spp. Hyphens indicate gaps. Colour scale from
minimal consensus (dark blue) to exact consensus (red).
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G6PD: Glucose-6-phosphate dehydrogenase; PQ: Primaquine; SSU RNA: Small
subunit rRNA.
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